A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients

OBJECTIVE: Anlotinib is a multitarget anti-angiogenic drug that combined with temozolomide (TMZ) can effectively prolongs the overall survival (OS) of recurrent malignant glioma(rMG),but some patients do not respond to anlotinib combined with TMZ. These patients were associated with a worse prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yurong, Xu, Weilin, Fei, Yinjiao, Wu, Mengxing, Yuan, Jinling, Qiu, Lei, Zhang, Yumeng, Chen, Guanhua, Cheng, Yu, Cao, Yuandong, Zhou, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447352/
https://www.ncbi.nlm.nih.gov/pubmed/37612579
http://dx.doi.org/10.1007/s12672-023-00751-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447352/
https://www.ncbi.nlm.nih.gov/pubmed/37612579
http://dx.doi.org/10.1007/s12672-023-00751-x

Ejemplares similares